newsfilter
← Latest News
GlobeNewswire·

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biotherapeutic programs